In 1971 Dr. Judah Folkman announced to the world that angiogenesis would be the Achilles heel of cancer-what's happened in the last 35 years? Dr. Walter M. Stadler, professor of medicine, director of Genitourinary Program, and associate dean of Clinical Research at the University of Chicago Medical Center joins host Dr. Bruce Bloom to fast forward from that early discovery to the current cutting edge uses for Avastin and other anti-angiogenics in cancer, including successes and shortcomings of this class of drugs in treating both solid tumors and blood cancers .
Angiogenetic Therapies for Cancer Treatment
Share
SaveShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
In 1971 Dr. Judah Folkman announced to the world that angiogenesis would be the Achilles heel of cancer-what's happened in the last 35 years? Dr. Walter M. Stadler, professor of medicine, director of Genitourinary Program, and associate dean of Clinical Research at the University of Chicago Medical Center joins host Dr. Bruce Bloom to fast forward from that early discovery to the current cutting edge uses for Avastin and other anti-angiogenics in cancer, including successes and shortcomings of this class of drugs in treating both solid tumors and blood cancers .
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?